Notice of Proposed Sale · 144
uniQure N.V.
QURENASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- uniQure N.V.
- Issuer CIK
- 0001590560
- SEC file number
- 001-36294
- Phone
- 1-339-970-7000
- Person for whose account securities are to be sold
- Kapusta Matthew C
- Relationships to issuer
- Officer · Director · CEO AND MANAGING DIRECTOR
- Street
- PAASHEUVELWEG 25A
- City
- AMSTERDAM
- State / country code
- P7
- Postal code
- 1105 BP
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| ORDINARY SHARES | 21,082 | 951,931.59 | 63,067,485 | 07/02/2026 | NASDAQ | CITIGROUP GLOBAL MARKETS |
Broker / market maker — proposed row 1, entry 1
- Name
- CITIGROUP GLOBAL MARKETS
- Street
- 390 GREENWICH ST
- City
- NEW YORK
- State / country code
- NY
- Postal code
- 10013
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | 07/02/2026 | Stock option exercise and sale | UNIQURE NV | 21,082 | N | 07/02/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Kapusta Matthew C | ORDINARY SHARES | 06/17/2026 | 152,844 | 6,724,136.05 |
| Kapusta Matthew C | ORDINARY SHARES | 06/18/2026 | 11,585 | 563,610.25 |
| Kapusta Matthew C | ORDINARY SHARES | 06/18/2026 | 41,671 | 1,932,516.28 |
| Kapusta Matthew C | ORDINARY SHARES | 06/24/2026 | 6,696 | 334,800.00 |
| Kapusta Matthew C | ORDINARY SHARES | 06/25/2026 | 28,716 | 1,436,305.40 |
Seller — prior-sale row 1, entry 1
- Name
- Kapusta Matthew C
- Street
- PAASHEUVELWEG 25A
- City
- AMSTERDAM
- State / country code
- P7
- Postal code
- 1105BP
Seller — prior-sale row 2, entry 1
- Name
- Kapusta Matthew C
- Street
- PAASHEUVELWEG 25A
- City
- AMSTERDAM
- State / country code
- P7
- Postal code
- 1105BP
Seller — prior-sale row 3, entry 1
- Name
- Kapusta Matthew C
- Street
- PAASHEUVELWEG 25A
- City
- AMSTERDAM
- State / country code
- P7
- Postal code
- 1105BP
Seller — prior-sale row 4, entry 1
- Name
- Kapusta Matthew C
- Street
- PAASHEUVELWEG
- City
- AMSTERDAM
- State / country code
- P7
- Postal code
- 1105BP
Seller — prior-sale row 5, entry 1
- Name
- Kapusta Matthew C
- Street
- PAASHEUVELWEG 25A
- City
- AMSTERDAM
- State / country code
- P7
- Postal code
- 1105BP
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
Options were exercised and sold from established 10b51 plan adopted in October 2025.
Notice signature
- Notice date
- 07/02/2026
- Signed
- CONFORMED SIGNATURE ON FILE
- Plan adoption dates
- 10/05/2025
Company context
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B - an historic achievement based on more than a decade of research and clinical development - represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com